Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection

Elena Sbrana, Robert Jordan, Dennis E. Hruby, Rosa I. Mateo, Shu Yuan Xiao, Marina Siirin, Patrick C. Newman, Amelia P.A. Travassos Da Rosa, Robert B. Tesh

Research output: Contribution to journalArticlepeer-review

72 Scopus citations


Efficacy of the new antipoxvirus compound ST-246 was evaluated as treatment of monkeypox (MPX) virus infection in a ground squirrel model of the disease. Ground squirrels were given a lethal dose of MPX virus and were then treated orally at various times post-inoculation (pi) with 100 mg/kg/day of ST-246. Morbidity and mortality, clinical laboratory results, viral load, and pathology of placebo and treatment groups were compared. All animals that started treatment with ST-246 on days 0, 1, 2, and 3 pi survived lethal challenge with MPX virus; 67% of animals treated on day 4 pi also survived. In contrast, 100% of the placebo group died. Most of the ST-246-treated animals showed no evidence of clinical disease or alteration of baseline clinical laboratory values and had minimal histopathologic changes. These results suggest that ST-246 is a promising candidate for early treatment of severe orthopoxvirus infection.

Original languageEnglish (US)
Pages (from-to)768-773
Number of pages6
JournalAmerican Journal of Tropical Medicine and Hygiene
Issue number4
StatePublished - Apr 2007
Externally publishedYes

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology
  • Parasitology


Dive into the research topics of 'Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection'. Together they form a unique fingerprint.

Cite this